{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:40:40Z","timestamp":1791196840486,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T00:00:00Z","timestamp":1507075200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Shire Development LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s40263-017-0468-2","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T05:32:02Z","timestamp":1507095122000},"page":"999-1014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit\/Hyperactivity Disorder"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8993-9337","authenticated-orcid":false,"given":"Jeffrey H.","family":"Newcorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C.","family":"Childress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Frick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Pliszka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,4]]},"reference":[{"issue":"1","key":"468_CR1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/adc.2009.175943","volume":"95","author":"M Atkinson","year":"2010","unstructured":"Atkinson M, Hollis C. NICE guideline: attention deficit hyperactivity disorder. Arch Dis Child Educ Pract Ed. 2010;95(1):24\u20137.","journal-title":"Arch Dis Child Educ Pract Ed."},{"key":"468_CR2","doi-asserted-by":"crossref","unstructured":"Subcommittee on Attention-Deficit\/Hyperactivity Disorder Steering Committee on Quality Improvement and Management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007\u201322.","DOI":"10.1542\/peds.2011-2654"},{"issue":"6","key":"468_CR3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1089\/cap.2011.0018","volume":"21","author":"MA Stein","year":"2011","unstructured":"Stein MA, Waldman ID, Charney E, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011;21(6):581\u20138.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"468_CR4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/108705470000300403","volume":"3","author":"LE Arnold","year":"2000","unstructured":"Arnold LE. Methylphenidate vs. amphetamine: Comparative review. J Atten Disord. 2000;3(4):200\u20132011.","journal-title":"J Atten Disord"},{"issue":"7","key":"468_CR5","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/chi.0b013e318054e724","volume":"46","author":"S Pliszka","year":"2007","unstructured":"Pliszka S. AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894\u2013921.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"468_CR6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00787-009-0054-3","volume":"19","author":"SV Faraone","year":"2010","unstructured":"Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19(4):353\u201364.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"468_CR7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jad.2015.03.006","volume":"178","author":"M Stuhec","year":"2015","unstructured":"Stuhec M, Munda B, Svab V, et al. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. J Affect Disord. 2015;178:149\u201359.","journal-title":"J Affect Disord"},{"issue":"8","key":"468_CR8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00787-017-0962-6","volume":"26","author":"A Joseph","year":"2017","unstructured":"Joseph A, Ayyagari R, Xie M, et al. Comparative efficacy and safety of attention-deficit\/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry. 2017;26(8):875\u201397.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"7","key":"468_CR9","doi-asserted-by":"crossref","first-page":"e0180355","DOI":"10.1371\/journal.pone.0180355","volume":"12","author":"F Catala-Lopez","year":"2017","unstructured":"Catala-Lopez F, Hutton B, Nunez-Beltran A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS One. 2017;12(7):e0180355.","journal-title":"PLoS One"},{"issue":"8","key":"468_CR10","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1185\/03007995.2014.904772","volume":"30","author":"NS Roskell","year":"2014","unstructured":"Roskell NS, Setyawan J, Zimovetz EA, et al. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine. Curr Med Res Opin. 2014;30(8):1673\u201385.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"468_CR11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00004583-200005000-00016","volume":"39","author":"SR Pliszka","year":"2000","unstructured":"Pliszka SR, Browne RG, Olvera RL, et al. A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(5):619\u201326.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"468_CR12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40263-013-0086-6","volume":"27","author":"C Soutullo","year":"2013","unstructured":"Soutullo C, Banaschewski T, Lecendreux M, et al. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs. 2013;27(9):743\u201351.","journal-title":"CNS Drugs"},{"issue":"7","key":"468_CR13","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/00004583-199707000-00021","volume":"36","author":"J Kaufman","year":"1997","unstructured":"Kaufman J, Birmaher B, Brent D, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"468_CR14","volume-title":"ADHD rating scale-IV: checklists, norms, and clinical interpretation","author":"GJ DuPaul","year":"1998","unstructured":"DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD rating scale-IV: checklists, norms, and clinical interpretation. New York: Guilford Press; 1998."},{"key":"468_CR15","unstructured":"Guy W. Clinical Global Impressions. Rockville, MD: US Department of Health, Education, and Welfare; Public Health Service; Alcohol, Drug Abuse and Mental Health Administration; NIMH Psychopharmacology Research Branch; 1976."},{"key":"468_CR16","unstructured":"Posner K, Brent D, Lucas C, et al. Columbia-suicide severity rating scale. http:\/\/www.cssrs.columbia.edu\/scale_versions.html . Accessed 7 June 2016."},{"issue":"4","key":"468_CR17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaac.2011.01.007","volume":"50","author":"RL Findling","year":"2011","unstructured":"Findling RL, Childress AC, Cutler AJ, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(4):395\u2013405.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"468_CR18","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1176\/appi.ajp.2007.05091676","volume":"165","author":"JH Newcorn","year":"2008","unstructured":"Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165(6):721\u201330.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"468_CR19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1542\/peds.108.4.883","volume":"108","author":"ML Wolraich","year":"2001","unstructured":"Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit\/hyperactivity disorder. Pediatrics. 2001;108(4):883\u201392.","journal-title":"Pediatrics"},{"key":"468_CR20","unstructured":"Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD Practice Guidelines, Third Edition. Toronto, ON, Canada: CADDRA; 2011."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-017-0468-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0468-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0468-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T02:58:16Z","timestamp":1570157896000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-017-0468-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,4]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["468"],"URL":"https:\/\/doi.org\/10.1007\/s40263-017-0468-2","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,4]]}}}